About FDA
Total number of recall events in the month for which the classification process was completed
Dictionary: Using the recall process, manufacturers may voluntarily remove a drug from the marketplace if a drug quality defect is found. The Office of Compliance (OC) classifies the recall (or recommends classification in some cases) based on the level of public health risk. A Class I recall is the most significant recall. A recall may be done for a single product dosage form or for multiple dosage forms, or multiple products, therefore we report both the number of recall events and the number of products recalled.
These measures have been retired as CDER has created new measures for FY13 which align to their four functional areas of 1) Regulatory Review and Drug Safety, 2) Drug Quality and Compliance, 3) Transparency and Public Outreach, and 4) Regulatory Science Research.
Fiscal Year - 2011
| Time | Target | Number |
|---|---|---|
| Oct 2010 | N/A | 15 |
| Nov 2010 | N/A | 23 |
| Dec 2010 | N/A | 34 |
| Jan 2011 | N/A | 19 |
| Feb 2011 | N/A | 31 |
| Mar 2011 | N/A | 47 |
| Apr 2011 | N/A | 35 |
| May 2011 | N/A | 16 |
| Jun 2011 | N/A | 47 |
| Jul 2011 | N/A | 41 |
| Aug 2011 | N/A | 71 |
| Sep 2011 | N/A | 40 |
Number of Class I recalls classified by Office of Regulatory Affairs (ORA) after recommendation by CDER Compliance (1)
Fiscal Year - 2011
| Time | Target | Number |
|---|---|---|
| Oct 2010 | N/A | 3 |
| Nov 2010 | N/A | 2 |
| Dec 2010 | N/A | 4 |
| Jan 2011 | N/A | 4 |
| Feb 2011 | N/A | 3 |
| Mar 2011 | N/A | 2 |
| Apr 2011 | N/A | 7 |
| May 2011 | N/A | 2 |
| Jun 2011 | N/A | 4 |
| Jul 2011 | N/A | 0 |
| Aug 2011 | N/A | 8 |
| Sep 2011 | N/A | 4 |
Footnotes
- (1) Authority to designate a drug recall as Class I currently rests with the Associate Commissioner for Regulatory Affairs (ACRA)
Percent Class 1 recall events from tainted supplements
Performance measure implemented FY 2011
Fiscal Year - 2011
Performance measure implemented FY 2011
| Time | Target | Percent |
|---|---|---|
| Oct 2010 | N/A | 67 |
| Nov 2010 | N/A | 0 |
| Dec 2010 | N/A | 75 |
| Jan 2011 | N/A | 100 |
| Feb 2011 | N/A | 33 |
| Mar 2011 | N/A | 100 |
| Apr 2011 | N/A | 57 |
| May 2011 | N/A | 100 |
| Jun 2011 | N/A | TBA |
| Jul 2011 | N/A | 0 |
| Aug 2011 | N/A | 63 |
| Sep 2011 | N/A | 50 |
Number of products impacted by Class I recalls
Fiscal Year - 2011
| Time | Target | Number |
|---|---|---|
| Oct 2010 | N/A | 4 |
| Nov 2010 | N/A | 2 |
| Dec 2010 | N/A | 6 |
| Jan 2011 | N/A | 29 |
| Feb 2011 | N/A | 3 |
| Mar 2011 | N/A | 2 |
| Apr 2011 | N/A | 8 |
| May 2011 | N/A | 2 |
| Jun 2011 | N/A | 5 |
| Jul 2011 | N/A | 0 |
| Aug 2011 | N/A | 25 |
| Sep 2011 | N/A | 5 |
Percent of products impacted that are tainted supplements
Performance measure implemented FY 2011
Fiscal Year - 2011
Performance measure implemented FY 2011
| Time | Target | Percent |
|---|---|---|
| Oct 2010 | N/A | 75 |
| Nov 2010 | N/A | 0 |
| Dec 2010 | N/A | 67 |
| Jan 2011 | N/A | 100 |
| Feb 2011 | N/A | 33 |
| Mar 2011 | N/A | 100 |
| Apr 2011 | N/A | 63 |
| May 2011 | N/A | 100 |
| Jun 2011 | N/A | 60 |
| Jul 2011 | N/A | 0 |
| Aug 2011 | N/A | TBD |
| Sep 2011 | N/A | TBD |
Number of Class II recalls classified
Fiscal Year - 2011
| Time | Target | Number |
|---|---|---|
| Oct 2010 | N/A | 9 |
| Nov 2010 | N/A | 17 |
| Dec 2010 | N/A | 15 |
| Jan 2011 | N/A | 10 |
| Feb 2011 | N/A | 19 |
| Mar 2011 | N/A | 28 |
| Apr 2011 | N/A | 20 |
| May 2011 | N/A | 7 |
| Jun 2011 | N/A | 23 |
| Jul 2011 | N/A | 29 |
| Aug 2011 | N/A | 41 |
| Sep 2011 | N/A | 27 |
Number of products impacted by Class II recalls
Fiscal Year - 2011
| Time | Target | Number |
|---|---|---|
| Oct 2010 | N/A | 18 |
| Nov 2010 | N/A | 65 |
| Dec 2010 | N/A | 43 |
| Jan 2011 | N/A | 16 |
| Feb 2011 | N/A | 44 |
| Mar 2011 | N/A | 95 |
| Apr 2011 | N/A | 22 |
| May 2011 | N/A | 59 |
| Jun 2011 | N/A | 42 |
| Jul 2011 | N/A | 121 |
| Aug 2011 | N/A | 93 |
| Sep 2011 | N/A | 693 |
Glossary
Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.







